Published in Pharmacogenetics on November 01, 2002
First-pass metabolism via UDP-glucuronosyltransferase: a barrier to oral bioavailability of phenolics. J Pharm Sci (2011) 1.27
Quantitative prediction of in vivo inhibitory interactions involving glucuronidated drugs from in vitro data: the effect of fluconazole on zidovudine glucuronidation. Br J Clin Pharmacol (2006) 1.12
Three-dimensional quantitative structure-activity relationship studies on UGT1A9-mediated 3-O-glucuronidation of natural flavonols using a pharmacophore-based comparative molecular field analysis model. J Pharmacol Exp Ther (2010) 0.97
Regioselective glucuronidation of flavonols by six human UGT1A isoforms. Pharm Res (2011) 0.89
Quantitative assessment of the multiple processes responsible for bilirubin homeostasis in health and disease. Clin Exp Gastroenterol (2014) 0.85
Understanding substrate selectivity of human UDP-glucuronosyltransferases through QSAR modeling and analysis of homologous enzymes. Xenobiotica (2012) 0.81
Accurate prediction of glucuronidation of structurally diverse phenolics by human UGT1A9 using combined experimental and in silico approaches. Pharm Res (2012) 0.80
Nomenclature update for the mammalian UDP glycosyltransferase (UGT) gene superfamily. Pharmacogenet Genomics (2005) 2.98
Time course of sympathetic neural hyperactivity after uncomplicated acute myocardial infarction. Circulation (2002) 1.61
Sympathetic neural hyperactivity and its normalization following unstable angina and acute myocardial infarction. Clin Sci (Lond) (2004) 1.58
Metabolic programming and PDHK1 control CD4+ T cell subsets and inflammation. J Clin Invest (2014) 1.58
Human udp-glucuronosyltransferases: isoform selectivity and kinetics of 4-methylumbelliferone and 1-naphthol glucuronidation, effects of organic solvents, and inhibition by diclofenac and probenecid. Drug Metab Dispos (2004) 1.51
Blood pressure rising: differences between current clinical and recommended measurement techniques. J Am Soc Hypertens (2011) 1.44
Selectivity of substrate (trifluoperazine) and inhibitor (amitriptyline, androsterone, canrenoic acid, hecogenin, phenylbutazone, quinidine, quinine, and sulfinpyrazone) "probes" for human udp-glucuronosyltransferases. Drug Metab Dispos (2005) 1.41
The UDP-glucuronosyltransferases: their role in drug metabolism and detoxification. Int J Biochem Cell Biol (2013) 1.39
Determination of the role of conventional, novel and atypical PKC isoforms in the expression of morphine tolerance in mice. Pain (2006) 1.37
Isoform selectivity and kinetics of morphine 3- and 6-glucuronidation by human udp-glucuronosyltransferases: evidence for atypical glucuronidation kinetics by UGT2B7. Drug Metab Dispos (2003) 1.30
Genetic polymorphisms of UDP-glucuronosyltransferases and their functional significance. Toxicology (2002) 1.29
In vitro characterization of lamotrigine N2-glucuronidation and the lamotrigine-valproic acid interaction. Drug Metab Dispos (2006) 1.20
Educating our students about pharmaceutical care for those living with cancer. Am J Pharm Educ (2012) 1.20
Predicting human drug glucuronidation parameters: application of in vitro and in silico modeling approaches. Annu Rev Pharmacol Toxicol (2004) 1.13
Quantitative prediction of in vivo inhibitory interactions involving glucuronidated drugs from in vitro data: the effect of fluconazole on zidovudine glucuronidation. Br J Clin Pharmacol (2006) 1.12
Consumers' views of pharmacogenetics--A qualitative study. Res Social Adm Pharm (2010) 1.07
Influence of mutations associated with Gilbert and Crigler-Najjar type II syndromes on the glucuronidation kinetics of bilirubin and other UDP-glucuronosyltransferase 1A substrates. Pharmacogenet Genomics (2007) 1.07
Binding of inhibitory fatty acids is responsible for the enhancement of UDP-glucuronosyltransferase 2B7 activity by albumin: implications for in vitro-in vivo extrapolation. J Pharmacol Exp Ther (2007) 1.06
The configuration of the 17-hydroxy group variably influences the glucuronidation of beta-estradiol and epiestradiol by human UDP-glucuronosyltransferases. Drug Metab Dispos (2008) 1.05
High incidence of spontaneous disease in an HLA-DR15 and TCR transgenic multiple sclerosis model. J Immunol (2005) 1.04
PKC and PKA inhibitors reinstate morphine-induced behaviors in morphine tolerant mice. Pharmacol Res (2006) 1.02
In vitro-in vivo extrapolation of zolpidem as a perpetrator of metabolic interactions involving CYP3A. Eur J Clin Pharmacol (2009) 1.02
Identification of UDP glycosyltransferase 3A1 as a UDP N-acetylglucosaminyltransferase. J Biol Chem (2008) 1.02
S-Naproxen and desmethylnaproxen glucuronidation by human liver microsomes and recombinant human UDP-glucuronosyltransferases (UGT): role of UGT2B7 in the elimination of naproxen. Br J Clin Pharmacol (2005) 1.01
Cannabinoid receptor agonists are mitochondrial inhibitors: a unified hypothesis of how cannabinoids modulate mitochondrial function and induce cell death. Biochem Biophys Res Commun (2007) 1.00
An evaluation of potential mechanism-based inactivation of human drug metabolizing cytochromes P450 by monoamine oxidase inhibitors, including isoniazid. Br J Clin Pharmacol (2006) 1.00
Biozzi mice: of mice and human neurological diseases. J Neuroimmunol (2005) 0.99
Vanilloid receptor agonists and antagonists are mitochondrial inhibitors: how vanilloids cause non-vanilloid receptor mediated cell death. Biochem Biophys Res Commun (2007) 0.98
Autoimmunity against myelin oligodendrocyte glycoprotein is dispensable for the initiation although essential for the progression of chronic encephalomyelitis in common marmosets. J Neuropathol Exp Neurol (2008) 0.98
Kinetic modeling of the interactions between 4-methylumbelliferone, 1-naphthol, and zidovudine glucuronidation by udp-glucuronosyltransferase 2B7 (UGT2B7) provides evidence for multiple substrate binding and effector sites. Mol Pharmacol (2008) 0.98
A potent and selective S1P(1) antagonist with efficacy in experimental autoimmune encephalomyelitis. Chem Biol (2012) 0.98
Inhibition of human drug-metabolising cytochrome P450 and UDP-glucuronosyltransferase enzyme activities in vitro by uremic toxins. Eur J Clin Pharmacol (2014) 0.97
Partial charge calculation method affects CoMFA QSAR prediction accuracy. J Chem Inf Model (2009) 0.96
Impact of the UGT1A1*28 allele on response to irinotecan: a systematic review and meta-analysis. Pharmacogenomics (2012) 0.96
A new species of Antherospora supports the systematic placement of its host plant. IMA Fungus (2011) 0.95
The "albumin effect" and drug glucuronidation: bovine serum albumin and fatty acid-free human serum albumin enhance the glucuronidation of UDP-glucuronosyltransferase (UGT) 1A9 substrates but not UGT1A1 and UGT1A6 activities. Drug Metab Dispos (2008) 0.95
Non-selective nonsteroidal anti-inflammatory drugs and cardiovascular events: is aldosterone the silent partner in crime? Br J Clin Pharmacol (2006) 0.95
Defining the COX inhibitor selectivity of NSAIDs: implications for understanding toxicity. Expert Rev Clin Pharmacol (2010) 0.95
High throughput analysis of red wine and grape phenolics-adaptation and validation of methyl cellulose precipitable tannin assay and modified Somers color assay to a rapid 96 well plate format. J Agric Food Chem (2007) 0.95
Quantitative prediction of macrolide drug-drug interaction potential from in vitro studies using testosterone as the human cytochrome P4503A substrate. Eur J Clin Pharmacol (2006) 0.94
Evidence that unsaturated fatty acids are potent inhibitors of renal UDP-glucuronosyltransferases (UGT): kinetic studies using human kidney cortical microsomes and recombinant UGT1A9 and UGT2B7. Biochem Pharmacol (2004) 0.93
Disease-related epitope spread in a humanized T cell receptor transgenic model of multiple sclerosis. Eur J Immunol (2004) 0.93
TRPV1 and CB(1) receptor-mediated effects of the endovanilloid/endocannabinoid N-arachidonoyl-dopamine on primary afferent fibre and spinal cord neuronal responses in the rat. Eur J Neurosci (2004) 0.91
Amino terminal domains of human UDP-glucuronosyltransferases (UGT) 2B7 and 2B15 associated with substrate selectivity and autoactivation. Biochem Pharmacol (2006) 0.91
Perpetrators of pharmacokinetic drug-drug interactions arising from altered cytochrome P450 activity: a criteria-based assessment. Br J Clin Pharmacol (2011) 0.91
Comparison of linear and nonlinear classification algorithms for the prediction of drug and chemical metabolism by human UDP-glucuronosyltransferase isoforms. J Chem Inf Comput Sci (2003) 0.90
In vitro-in vivo extrapolation predicts drug-drug interactions arising from inhibition of codeine glucuronidation by dextropropoxyphene, fluconazole, ketoconazole, and methadone in humans. J Pharmacol Exp Ther (2010) 0.90
Innervation of gonadotropin-releasing hormone neurons by peptidergic neurons conveying circadian or energy balance information in the mouse. PLoS One (2009) 0.90
Mechanism-based inactivation of human cytochrome P4502C8 by drugs in vitro. J Pharmacol Exp Ther (2004) 0.89
The novel UDP glycosyltransferase 3A2: cloning, catalytic properties, and tissue distribution. Mol Pharmacol (2010) 0.89
In vitro-in vivo correlations for drugs eliminated by glucuronidation: investigations with the model substrate zidovudine. Br J Clin Pharmacol (2002) 0.89
PKC and PKA inhibitors reverse tolerance to morphine-induced hypothermia and supraspinal analgesia in mice. Eur J Pharmacol (2004) 0.89
In vitro approaches to investigate mechanism-based inactivation of CYP enzymes. Expert Opin Drug Metab Toxicol (2007) 0.89
Multiple pharmacophores for the investigation of human UDP-glucuronosyltransferase isoform substrate selectivity. Mol Pharmacol (2004) 0.88
Pharmacists' role in targeted cancer therapy in Australia and implications for pharmacy education. Am J Pharm Educ (2010) 0.88
Does health affect portfolio choice? Health Econ (2010) 0.87
The "albumin effect" and in vitro-in vivo extrapolation: sequestration of long-chain unsaturated fatty acids enhances phenytoin hydroxylation by human liver microsomal and recombinant cytochrome P450 2C9. Drug Metab Dispos (2008) 0.87
The glucuronidation of R- and S-lorazepam: human liver microsomal kinetics, UDP-glucuronosyltransferase enzyme selectivity, and inhibition by drugs. Drug Metab Dispos (2013) 0.87
Atorvastatin-induced cell toxicity in yeast is linked to disruption of protein isoprenylation. FEMS Yeast Res (2009) 0.86
Transcriptional regulation of human UDP-glucuronosyltransferase genes. Drug Metab Rev (2014) 0.86
Longer ice-free seasons increase the risk of nest depredation by polar bears for colonial breeding birds in the Canadian Arctic. Proc Biol Sci (2014) 0.86
Is urinary indolyl-3-acryloylglycine a biomarker for autism with gastrointestinal symptoms? Biomarkers (2009) 0.86
Prediction of metabolism by cytochrome P450 2C9: alignment and docking studies of a validated database of substrates. J Med Chem (2008) 0.86
Quality of requests for serum digoxin concentrations: experience from an Australian regional health service. Br J Clin Pharmacol (2006) 0.86
Somatostatin inhibits oxidative respiration in pancreatic beta-cells. Endocrinology (2005) 0.86
Morphine glucuronidation and glucosidation represent complementary metabolic pathways that are both catalyzed by UDP-glucuronosyltransferase 2B7: kinetic, inhibition, and molecular modeling studies. J Pharmacol Exp Ther (2014) 0.85
Human renal cortical and medullary UDP-glucuronosyltransferases (UGTs): immunohistochemical localization of UGT2B7 and UGT1A enzymes and kinetic characterization of S-naproxen glucuronidation. J Pharmacol Exp Ther (2007) 0.85
Effects of Neospora caninum infection on brain microvascular endothelial cells bioenergetics. Parasit Vectors (2013) 0.85
The glycosidation of xenobiotics and endogenous compounds: versatility and redundancy in the UDP glycosyltransferase superfamily. Pharmacol Ther (2012) 0.85
Recent advances in the in silico modelling of UDP glucuronosyltransferase substrates. Curr Drug Metab (2008) 0.84
Renal drug metabolism in humans: the potential for drug-endobiotic interactions involving cytochrome P450 (CYP) and UDP-glucuronosyltransferase (UGT). Br J Clin Pharmacol (2013) 0.84
Amino acid conjugation: contribution to the metabolism and toxicity of xenobiotic carboxylic acids. Expert Opin Drug Metab Toxicol (2007) 0.84
Degradation of white wine haze proteins by Aspergillopepsin I and II during juice flash pasteurization. Food Chem (2012) 0.84
Renal UDP-glucuronosyltransferases and the glucuronidation of xenobiotics and endogenous mediators. Drug Metab Rev (2010) 0.84
Differential contribution of active site residues in substrate recognition sites 1 and 5 to cytochrome P450 2C8 substrate selectivity and regioselectivity. Biochemistry (2004) 0.84
Effect of albumin on human liver microsomal and recombinant CYP1A2 activities: impact on in vitro-in vivo extrapolation of drug clearance. Drug Metab Dispos (2012) 0.84
Identification of the human cytochromes P450 catalysing the rate-limiting pathways of gliclazide elimination. Br J Clin Pharmacol (2007) 0.83
Aldosterone glucuronidation by human liver and kidney microsomes and recombinant UDP-glucuronosyltransferases: inhibition by NSAIDs. Br J Clin Pharmacol (2009) 0.83
Pathological and regulatory effects of anti-myelin antibodies in experimental allergic encephalomyelitis in mice. J Neuroimmunol (2002) 0.83
Effects of amino acid substitutions at positions 33 and 37 on UDP-glucuronosyltransferase 1A9 (UGT1A9) activity and substrate selectivity. Biochem Pharmacol (2012) 0.83
Characterization of the binding of drugs to human intestinal fatty acid binding protein (IFABP): potential role of IFABP as an alternative to albumin for in vitro-in vivo extrapolation of drug kinetic parameters. Drug Metab Dispos (2009) 0.83
Pharmacophore and quantitative structure-activity relationship modeling: complementary approaches for the rationalization and prediction of UDP-glucuronosyltransferase 1A4 substrate selectivity. J Med Chem (2003) 0.82
Relationship between hyperbilirubinaemia and UDP-glucuronosyltransferase 1A1 (UGT1A1) polymorphism in adult HIV-infected Thai patients treated with indinavir. Pharmacogenet Genomics (2006) 0.82
Characterisation of the binding of cationic amphiphilic drugs to phospholipid bilayers using surface plasmon resonance. ChemMedChem (2007) 0.82
In vitro characterisation of human renal and hepatic frusemide glucuronidation and identification of the UDP-glucuronosyltransferase enzymes involved in this pathway. Biochem Pharmacol (2008) 0.82
Carboxylic acid drug-induced DNA nicking in HEK293 cells expressing human UDP-glucuronosyltransferases: role of acyl glucuronide metabolites and glycation pathways. Chem Res Toxicol (2007) 0.82
Personalized medicine: potential, barriers and contemporary issues. Curr Drug Metab (2012) 0.82
Assessment of inter-individual variability in predicted phenytoin clearance. Eur J Clin Pharmacol (2009) 0.81
The importance of local chemical structure for chemical metabolism by human uridine 5'-diphosphate-glucuronosyltransferase. J Chem Inf Model (2006) 0.81
Comparison data sets for benchmarking QSAR methodologies in lead optimization. J Chem Inf Model (2009) 0.81
Factors affecting skin tannin extractability in ripening grapes. J Agric Food Chem (2014) 0.81